0001555667-16-000060.txt : 20160309 0001555667-16-000060.hdr.sgml : 20160309 20160309205053 ACCESSION NUMBER: 0001555667-16-000060 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160308 FILED AS OF DATE: 20160309 DATE AS OF CHANGE: 20160309 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SOLAZYME INC CENTRAL INDEX KEY: 0001311230 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL ORGANIC CHEMICALS [2860] IRS NUMBER: 331077078 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 225 GATEWAY BLVD. CITY: S. SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-780-4777 MAIL ADDRESS: STREET 1: 225 GATEWAY BLVD. CITY: S. SAN FRANCISCO STATE: CA ZIP: 94080 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Quinlan Paul T CENTRAL INDEX KEY: 0001333277 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35189 FILM NUMBER: 161495962 BUSINESS ADDRESS: BUSINESS PHONE: (650) 780-4777 MAIL ADDRESS: STREET 1: SOLAZYME, INC. STREET 2: 225 GATEWAY BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2016-03-08 0001311230 SOLAZYME INC SZYM 0001333277 Quinlan Paul T SOLAZYME, INC. 225 GATEWAY BOULEVARD SOUTH SAN FRANCISCO CA 94080 0 1 0 0 General Counsel Common Stock 2016-03-08 4 S 0 1562 1.6646 D 75193 D Common Stock 2016-03-08 4 A 0 62500 0 A 137693 D Employee Stock Option (right to buy) 1.66 2016-03-08 4 A 0 350000 0 A 2026-03-07 Common Stock 350000 350000 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was designed to cover tax withholding obligations in connection with the concurrent vesting of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.63 to $1.69, inclusive. The reporting person undertakes to provide to Solazyme, Inc., any security holder of Solazyme, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The grant shall vest as to 1/4 of the shares on March 9, 2017 and thereafter shall vest as to 1/8 of the shares on each of September 14, 2017, March 8, 2018, September 14, 2018, March 1, 2019, September 11, 2019 and March 11, 2020. The option shall vest as to 1/48 of the underlying shares monthly beginning on February 1, 2016. /s/ Rob Maynes, as attorney-in-fact 2016-03-09